

CONTENTS

ABOUT THE EDITOR	xvii
ABOUT THE AUTHORS	xix
PREFACE BY HENRY CHESBROUGH	xxix

PART I PRINCIPLES OF GLOBAL LEADERSHIP IN THE ENDURING TECHNOLOGY COMPANY 1

1 THE POLYMATH CEO: ENLIGHTENED LEADERSHIP FOR THE ENDURING TECHNOLOGY COMPANY 3

EDWARD KAHN

The Global Picture from a Lofty Perch	3
What's at Stake	6
Restructuring Financial Incentives	8
IP and Business Strategy Must Be Congruent	9
Disintermediation of RD&E	13
Varied Paths of Innovation	15
Open Innovation and Disruptive Technologies	22
Merger Mania vs. Tech Transfer	25
Wide IP Vision as an Antidote to Trolls	27
Sustainability Requires Constant Change	29

PART 2 INTELLECTUAL PROPERTY MANAGEMENT 31

2 THE IP TOOLKIT: MAXIMIZING BUSINESS VALUE FROM INTELLECTUAL PROPERTY 33

EDMUND WALSH

The First Rule of Value: Intellectual Property Doesn't Do Anything (on Its Own)	33
--	----

X CONTENTS

The Nature of IP Rights	34
Business Actions that Generate Value	35
Beyond Portfolio Mining	36
The Second Rule of Value: Rational People Don't Sue Themselves	39
Threats and Opportunities	40
The Spectrum of Business Models	41
The Third Rule of Value: "Patience and Diligence Remove Mountains"— <i>William Penn</i>	45
Top-Down and Bottom-Up Execution	46
Conclusion	48

3 HARVESTING NEW INTELLECTUAL ASSETS: THE ROLE OF BUSINESS METHOD PATENTS AND TRADE SECRETS IN STRATEGIC IP MANAGEMENT 49

KARL JORDA and WAYNE JAESCHKE

The Fusion of Marketing, Technology, and IP in Integrated IP Management	49
<i>State Street Bank</i> Leads to an Explosion of Financial and E-Commerce Patents	53
The Debate over Patenting Business Methods and Nontechnical Subject Matter	54
Jeffersonian Liberal Encouragement of Innovation	54
The Doomsday Scenario if Nontechnology Patents Are Not Reined In	55
Litigation of Business Methods	57
Using Business Method Patents to Protect Core Market Interests beyond Finance and E-Commerce	58
Major Users	58
Other Users	59
Dovetail Business Method Patents and Trade Secrets	62
The Role and Value of Trade Secrets in Conjunction with Patents	62
Exemplary Trade-Secret Cases	66
Connecting Business and Marketing with Innovation and IP Protection	68
Business, Technical, and IP Partnering to Pollinate the Seeds and Harvest the Fruit	69
Capturing All of the Innovation for Added Shareholder Value	70

4 GIANTS CAN BE NIMBLE: THE SBC STORY 73**ABHA DIVINE**

Shifts in Innovation	73
Valuation of IP Assets	74
IP Management Styles	76
Defend and Protect	76
Develop and Drive	76
Market and Commercialize	77
The SBC Communications Story	79
Organizational Approach	82
Portfolio Management	83
Business Development	87
Finance	92
Legal	96
Operational Controls	98
Operational and Financial Metrics	99
Conclusions	101

5 INNOVATION ASSET PORTFOLIO: THE INTELLECTUAL PROPERTY MUSE GETS AN MBA 103**DAMON MATTEO**

Finding Value in Innovation	104
Moving R&D into Accountability	105
A New Methodology	107
Measures of Value	108
Legal	109
Technical	110
Market	110
Linkages and Dependencies	112
Profit/Revenue	113
Cost	114
Risk	115
Selection of Research Targets	116
Multiple Commercialization Vehicles	119

PART 3 INNOVATION 123

6 INNOVATION STRATEGY: THE ESSENTIAL INGREDIENT 125

MICHAEL KAYAT

Introduction	125
Need for Innovation: The Strategy Review	126
Fuel and Guidance for Innovation	127
Nature of Innovation	128
Sources of Innovation	128
Innovation Models	128
Current Issues with Innovation	132
Innovation Value Gap	133
Uncovering New Ideas and Opportunities	134
Patent Portfolio Paradox	135
Best Practices for Strategic IP Management	137
IP Strategies for Disruptive Innovation	137
IP Strategies for Open Innovation	138
IP as a Core Strategic Element	140
IP Portfolio Optimization	142
Executive and Board Support	147
Conclusions	148

7 MAXIMIZING INNOVATION TEAMS: THE INTERNAL AND EXTERNAL CONNECTION NETWORK 149

CARSTEN WITTRUP

Case Story	150
New Approach	152
Innovation Teams and Networks	153
Innovation Team Member Selection Criteria	156
Team Function and Roles	158
Team Leader	160
The Connectors	161
Team Communication	161
The Innovation Team Test Drive	162

**8 ROAD-MAPPING DISRUPTIVE TECHNICAL THREATS AND OPPORTUNITIES IN
COMPLEX, TECHNOLOGY-BASED SUBSYSTEMS: THE SAILS METHODOLOGY 165**
BRUCE VOJAK and FRANK CHAMBERS

Background	165
The SAILS Methodology	172
Examples	176
Example 1: Frequency Generation Subsystems in Wireless Communication Super-Systems	176
Example 2: Optical Multiplexing Subsystems in Optical Communication Super-Systems	179
Example 3: High Voltage Electrical Subsystems in Automotive Super-Systems	183
Concluding Observations	185
Acknowledgments	186

PART 4 PARTNERED TECHNOLOGY AND BUSINESS DEVELOPMENT 187

9 OPEN FOR BUSINESS: THE AIR PRODUCTS AND CHEMICALS STORY 189
JOHN TAO and VINCENT MAGNITTA

Background on Open Innovation at Air Products and Chemicals, Inc.	189
Process for Needs Identification	190
Partnering Strategies	191
University R&D Alliances	194
Benefits of Industry-University Research Projects	194
Foundations for Success	196
Intellectual Property Rights	197
Compensation	199
Publication and Secrecy	202
Other Issues	203
Global R&D Insourcing	204
Experience in Russia	204
Experience in China	206
External Providers	208

Partnering with the Government 209
Licensing-In 211
Joint Development 211
Measuring External R&D Programs 212
Recognizing External Technologists or Partners 214

**APPENDIX 9A: DETERMINING FAIR ROYALTY RATES FOR UNIVERSITY-DEVELOPED
TECHNOLOGY EXCLUSIVE LICENSE OPTION 215**

Profitability of Air Products (APD) and Companies in Our Chemicals
Market Segment 215
University and Corporate Costs of Product R&D and
Commercialization 216
Approach 1: Royalty Rate as Function of Sales for Early-Stage
Technology 218
Approach 2: Royalty Rates Based on Earnings for Early Stage
Technology 220
Conclusion 222

**10 DEVELOPING GROWTH STRATEGIES USING INTELLECTUAL ASSETS
AND STRATEGIC ALLIANCES 223**

DENNIS McCULLOUGH

The Importance of Business Growth 223
SBU's as a Growth Vehicle 224
Tale of an SBU: Three Guys in a Garage 225
Lummus Process Technology 229
LPT's Strategy for Growth 229
How Can a Small Technology-Based Business Be a Growth Engine? 230
LPT History 230
Strategic Alliances for Small Business Unit Growth 236
The Key Alliance Success Factors 241
In a Nutshell 243

**11 INNOVATION AND THE BIOPHARMACEUTICAL INDUSTRY:
CRISIS OR CROSSROADS? 245**

RONALD LINDSAY

Introduction 246
Current Woes of the Pharmaceutical Industry 247
The Broken Pipeline 247

From Paragon of Virtue to Pariah in the Blink of an Eye	252
Reduced Productivity Not Explained by Revenue Shortfall, R&D Spending, or Lagging Innovation in Basic Science	252
No Decline in Overall R&D Spending in the Combined Biopharmaceutical Industry	253
What's the Problem—Is There a Solution and Is There a Bright Future?	253
Caught in the Headlights	256
Bright Future? Unmet Need and Increased Global Demand Will Reshape The Industry	257
Origins of the Industry Reveal Some Insights into the Broken Pipeline Problem	258
Blossoming of Synthetic Organic Chemistry Creates the Pharmaceutical Industry	258
Low-Hanging Fruit and Limited Competition	259
Peaks Scaled but Still in the Foothills	259
Failure to Invest in Preventative Maintenance and Competitive Insurance	260
Winds of Change: New Technologies, New Innovators, and a New Product Class	261
Elements of a “Perfect Storm”	261
Innovation at Breakneck Speed Creates Confusion and Fear of Missing the IP Boat	262
Gusher for Patent Attorneys—Who Owns What and Can I Get a Piece of It?	263
Irrational Exuberance—High Cost, Low Quality	264
Mega-Mergers—Short-Term Fix That Derails Innovation and Productivity	264
Product Liability—Lighting Strikes That Kill the Golden Goose	265
New Kids on the Block—Generics and Biotech	266
Generics—Eroding a Fair Return on Investment or a Spur to Innovation in R&D and Patent Strategies?	267
Biotechs—The Upstarts Who Dared	268
High-Stakes IP Legal Battles Sharpen the Mind	270
Recasting the Game for an Even Bigger Win	270
Big Pharma Fights Back (or Not): Exploiting Innovation and IP Developed by Others	271
Failing to Exploit Technical Advantage	271
Do Recent Trends Predict Successful Stenting of the Pipeline?	272
Recent Cancer Success Indicates Innovation Is Alive and Well	272
Antibodies As Drugs—If at First You Don't Succeed . . .	273

xvi CONTENTS

New Cutting Edge but Lots of Room for Improvement 274
The Future: Personalized Medicine, Integrated Innovation,
and Global Health 274
Global Health Issues 276
New Therapeutic Modalities—Soon to Be in the Spotlight 276
Conclusions 278
Bumpy Skies before Reaching Clear Air 278

12 BUILDING COMPANIES ON NOT-SO-FERTILE SOIL 281

TERI WILLEY

Introduction 281
Impediments and Missing Pieces 282
Aligning the Interests of Stakeholders 285
Step by Step, Deal by Deal 288
Conclusion 289

INDEX 291

<http://www.pbookshop.com>